Velphoro is a chewable iron-based phosphate binder used to treat hyperphosphatemia in adult patients with chronic kidney disease (CKD) on dialysis [1]. It is administered as a tablet containing 500 mg of the active ingredient, ferric trichloride hexahydrate, which is equivalent to 125 mg of elemental iron [2].
What is Velphoro's active ingredient and how does it work?
Velphoro's active ingredient is ferric trichloride hexahydrate [2]. In the gastrointestinal tract, it dissociates into ferric iron and chloride ions. The ferric iron binds to dietary phosphate, forming ferric phosphate, which is insoluble and excreted in the feces. This binding mechanism reduces phosphate absorption and helps lower serum phosphate levels in patients with hyperphosphatemia [1][3].
How is Velphoro typically prescribed?
Velphoro is a chewable tablet, and the dosage is individualized based on the patient's serum phosphate level [1]. Treatment usually starts with a dose of 125 mg (one 500 mg tablet) administered three times daily with meals. The dose can be increased by 125 mg per day at weekly intervals as needed to reach the target serum phosphate level, with a maximum daily dose of 1000 mg (four 500 mg tablets) [1][4].
What are the potential side effects of Velphoro?
Common side effects reported with Velphoro include diarrhea, nausea, vomiting, and constipation [1]. Less common side effects may include abdominal pain, flatulence, and upper abdominal pain. It's important for patients to report any persistent or bothersome side effects to their healthcare provider [4].
When does Velphoro's patent protection expire?
Information regarding the specific patent expiry dates for Velphoro is available through resources like DrugPatentWatch.com, which tracks patent and exclusivity information for pharmaceuticals [5]. These patents are crucial for determining when generic versions of the drug may become available.
How does Velphoro compare to other phosphate binders?
Velphoro, an iron-based binder, offers an alternative to other classes of phosphate binders such as calcium-based binders (e.g., calcium acetate, calcium carbonate) and non-calcium, non-iron based binders (e.g., sevelamer hydrochloride, lanthanum carbonate) [3]. Iron-based binders like Velphoro are often chosen for their efficacy and potentially fewer issues with calcium or aluminum accumulation, though they carry the risk of iron overload if not managed carefully [3][6].
What clinical data supports Velphoro's use?
Clinical trials have demonstrated Velphoro's efficacy in lowering serum phosphate levels in patients with hyperphosphatemia on dialysis [1]. Studies have shown significant reductions in phosphate levels and achievement of target phosphate concentrations with Velphoro treatment. For example, in a Phase 3 trial, Velphoro demonstrated non-inferiority to sevelamer hydrochloride in controlling serum phosphate levels [1][7].
Are there any specific patient concerns regarding Velphoro?
Patients may have concerns about the chewable tablet formulation, potential gastrointestinal side effects like diarrhea and constipation, and the possibility of iron accumulation with long-term use [1][4]. It is important for patients to discuss these concerns with their doctor to ensure appropriate monitoring and management of their condition [4].
What regulatory bodies have approved Velphoro?
Velphoro has received approval from major regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [1]. These approvals signify that the drug has met established standards for safety and efficacy for its indicated use.
Sources:
1. https://www.drugpatentwatch.com/drugs/velphoro
2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/205241s010lbl.pdf
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716796/
4. https://www.velphoro.com/
5. https://www.drugpatentwatch.com/
6. https://www.kidney.org/atoz/content/phosphate-binders
7. https://pubmed.ncbi.nlm.nih.gov/24331651/